Sovaprevir

Sovaprevir (codenamed ACH-1625) is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals. It acts as a NS3/4A inhibitor.[1]

Sovaprevir

Clinical data
Other names	ACH-1625
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name (4R)-N-{(1R,2S)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-1-{(2S)-3,3-dimethyl-2-[2-oxo-2-(1-piperidinyl)ethyl]butanoyl}-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolinamide
CAS Number	1001667-23-7
PubChem CID	53362096
ChemSpider	28529313
UNII	2ND9V3MN6O
KEGG	D10166
ChEMBL	ChEMBL2105750
NIAID ChemDB	491583
CompTox Dashboard (EPA)	DTXSID00142994
Chemical and physical data
Formula	C43H53N5O8S
Molar mass	799.98 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)[C@H](CC(=O)N1CCCCC1)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=CC(=NC6=C5C=CC(=C6)OC)C7=CC=CC=C7
InChI InChI=1S/C43H53N5O8S/c1-6-28-25-43(28,41(52)46-57(53,54)31-16-17-31)45-39(50)36-22-30(26-48(36)40(51)33(42(2,3)4)23-38(49)47-19-11-8-12-20-47)56-37-24-34(27-13-9-7-10-14-27)44-35-21-29(55-5)15-18-32(35)37/h6-7,9-10,13-15,18,21,24,28,30-31,33,36H,1,8,11-12,16-17,19-20,22-23,25-26H2,2-5H3,(H,45,50)(H,46,52)/t28-,30-,33-,36+,43-/m1/s1 Key:MHFMTUBUVQZIRE-WINRQGAFSA-N

Sovaprevir received Fast Track status from the U.S. Food and Drug Administration (FDA) in 2012.[2]

References

1. De Clercq E (June 2014). "Current race in the development of DAAs (direct-acting antivirals) against HCV". Biochemical Pharmacology. 89 (4): 441–52. doi:10.1016/j.bcp.2014.04.005. PMID 24735613.
2. "Sovaprevir HCV NS3/4A Protease Inhibitor". Achillion.

External links

• Achillion Provides Pipeline Update